XNAS · Healthcare · Drug Manufacturers - General
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest-revenue product, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-07-30 | Q2 2026 | 1.09 | 1.21 | +11.38% | $13.48B | ✅ Beat | +1.47% | +0.00% | +4.50% |
| 2026-04-23 | Q1 2026 | 1.06 | 1.10 | +3.77% | $12.31B | ✅ Beat | +3.60% | -2.00% | -6.82% |
| 2026-01-29 |
| Q4 2025 |
| 0.84 |
| 0.89 |
| +5.95% |
| $13.16B |
| ✅ Beat |
| +0.94% |
| +2.79% |
| +5.32% |
| 2025-10-24 | Q3 2025 | 1.60 | 1.70 | +6.31% | $14.54B | ✅ Beat | — | — | — |
| 2025-07-31 | Q2 2025 | 0.96 | 0.90 | — | $11.33B | ❌ Miss | — | — | — |
| 2025-04-24 | Q1 2025 | 0.95 | 0.94 | -0.95% | $10.41B | ❌ Miss | -2.28% | +1.05% | -2.15% |
| 2025-01-30 | Q4 2024 | 0.74 | 0.70 | -5.41% | $11.28B | ❌ Miss | +0.35% | -2.36% | +4.38% |
| 2024-10-25 | Q3 2024 | 1.39 | 1.57 | +12.95% | $14.77B | ✅ Beat | +0.04% | -1.97% | -11.02% |
Showing last 8 quarters.